Table 3.
Anti-PLA2R values of IMN patients in different histologic stages
| Stage | Overall (n = 374) | Anti-PLA2R positive (n = 256) | Anti-PLA2R negative (n = 118) | |||
|---|---|---|---|---|---|---|
|
|
|
|
||||
| No. (%) | Anti-PLA2R, RU/mL | No. (%) | Anti-PLA2R, RU/mL | No. (%) | Anti-PLA2R, RU/mL | |
| I | 250 (66.84) | 61.77 (10.01–161.54) | 163 (63.67) | 106.16 (69.11–228.54) | 87 (73.73) | 3.75 (< 2a–11.80) |
|
| ||||||
| II | 123 (32.89) | 66.95 (19.63–227.88) | 92 (35.94) | 109.84 (51.98–276.54) | 31(26.27) | 8.17 (2.29–14.20) |
|
| ||||||
| III | 1 (0.27) | 898.55 | 1 (0.39) | 898.55 | 0 | - |
|
| ||||||
| p value | 0.067 | 0.288 | 0.229 | |||
Values are presented as the median (interquartile range).
PLA2R, phospholipase A2 receptor; IMN, idiopathic membranous nephropathy.
a
The first quartile was below the lower limit of ELISA detection.